Abstract:Acute Lymphoblastic Leukemia (ALL) is the most common cancer in children, with a second incidence peak in adults over 60 years old. Long-term survival with currently available therapy regimens is >90% in children, but <50% in adults, reflecting differences in disease biology and tolerance of aggressive multi-agent chemotherapy regimens. While CAR-T cell therapy provides effective salvage to patients with relapsed B-cell ALL (B-ALL), outcome in relapsed T-ALL is exceptionally poor. In addition, therapy-related chronic functional impairment in pediatric ALL survivors are common. Less toxic, and more effective therapies are needed to improve ALL survival, particularly in adults, and reduce toxicity and functional impairment in all patients. There is evidence that energy restriction creates a barrier to malignant transformation as B cell precursors undergo somatic hypermutation and during T cell receptor diversification. Mutational inactivation of B-lineage transcription factors such as IKZF1 and PAX5 in B-ALL and aberrant expression of T-lineage regulators such as TLX1/3 in T-ALL disables this metabolic brake, promoting malignant transformation of B and T lymphoid precursors, respectively. Metabolism is being recognized as an attractive target in cancer therapy, but metabolic plasticity often limits the efficacy of targeting single metabolic pathways. SIRT5 is a lysine deacylase that regulates multiple metabolic pathways, including energy metabolism. We have previously reported that a subset of acute myeloid leukemia (AML) cases depends on SIRT5 as a master regulator of central energy metabolism, implicating SIRT5 as a therapy target in AML. We hypothesized that this metabolic vulnerability may extend to ALL. To study the function of SIRT5 in ALL, we stably expressed doxycycline (Dox)-inducible shRNAs targeting SIRT5 in ALL cell lines and primary samples. Knockdown (KD) of SIRT5 significantly inhibited growth and increased apoptosis in B-ALL and T-ALL cell lines. Similar results were seen with primary cells relapsed ALL, whereas SIRT5 KD had no effect on colony formation by normal CD34 + cord blood cells. We also injected mice with Jurkat T-ALL cells expressing Dox-inducible sh SIRT5 and luciferase. Dox-induced SIRT5 KD abrogated disease initiation and eliminated established disease (Figure 1A). To determine whether ALL cells require SIRT5 to maintain a metabolic state that is permissive to malignant transformation, we next evaluated the effect of SIRT5 disruption on energy metabolism, using Seahorse extracellular flux analysis. We found that SIRT5 deficient T-ALL cells had lower rates of both oxidative phosphorylation and glycolysis in comparison to SIRT5 wild type (WT) cells (Figure 1B). Next, to evaluate dependency of SIRT5-KD on multiple genotypes and therapy-resistant ALL, we engineered 30 ALL cell lines to stably express doxycycline sh SIRT5 representing B and T cell origin, diverse genotypes, and including drug resistant lines. We found that several B-ALL and T-ALL cell lines are highly dependent on SIRT5 for growth and survival, while others are not, showing a large range of sensitivity to SIRT5 KD. Therefore, to elucidate the potential mechanisms underlying SIRT5 dependence in ALL, we first analyzed whether SIRT5 KD differentially affects OXPHOS and glycolysis. Preliminary analysis of mitochondrial respiration upon SIRT5 KD suggested that OXPHOS and glycolysis are reduced in SIRT5-dependent cells, but not in SIRT5-independent cells upon SIRT5 KD. Finally, to determine whether Sirt5 disruption affects energy metabolism in normal hematopoietic stem cells (HSCs), we generated a tamoxifen-inducible conditional hematopoietic cell-specific Sirt5 knockout (KO) model. In preliminary experiments, we found no difference in mitochondrial respiration between normal HSCs with or without genetic absence of Sirt5, suggesting that leukemic cells, but not normal hematopoietic stem cells are dependent on Sirt5 for regulation of energy metabolism. Collectively, our results suggest that SIRT5 plays a critical oncogenic role in the development and maintenance of a subset of ALL, providing a rationale for the development of a clinical SIRT5 inhibitor. Targeting master regulators rather than single pathways may circumvent plasticity-based resistance in ALL.

SIRT1 Regulates the Phosphorylation and Degradation of P27 by Deacetylating CDK2 to Promote T-cell Acute Lymphoblastic Leukemia Progression.

SIRT5 Regulates Energy Metabolism and Survival in Acute Lymphoblastic Leukemia Cells

Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.

Activation of SIRT1 Deacetylase As a Therapeutic Approach for Myelodysplastic Syndromes By Restoring TET2 Function

SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia

Notch-1 Regulates Akt Signaling Pathway and the Expression of Cell Cycle Regulatory Proteins Cyclin D1, CDK2 and P21 in T-ALL Cell Lines

AML1-ETO Promotes SIRT1 Expression to Enhance Leukemogenesis of T(8;21) Acute Myeloid Leukemia.

Notch1 Signaling is Involved in Regulating Foxp3 Expression in T-ALL.

SIRT1 Downregulation Enhances Chemosensitivity and Survival of Adult T-cell Leukemia-Lymphoma Cells by Reducing DNA Double-Strand Repair.

SIRT2 Inhibits Non-Small Cell Lung Cancer Cell Growth Through Impairing Skp2-mediated P27 Degradation

SIRT1 Inhibition Impairs Non-Homologous End Joining DNA Damage Repair by Increasing Ku70 Acetylation in Chronic Myeloid Leukemia Cells

Interconnecting Molecular Pathways in the Pathogenesis and Drug Sensitivity of T-cell Acute Lymphoblastic Leukemia

Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies

Role of SIRT1 in Hematologic Malignancies.

PD-1 Signalling Defines and Protects Leukaemic Stem Cells from T Cell Receptor-Induced Cell Death in T Cell Acute Lymphoblastic Leukaemia

USP1 promotes the aerobic glycolysis and progression of T-cell acute lymphoblastic leukemia via PLK1/LDHA axis

Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies*

A novel tumor suppressor sh2b3 in acute lymphoblastic leukemia

Inhibition of BCL11B Induces Downregulation of PTK7 and Results in Growth Retardation and Apoptosis in T-cell Acute Lymphoblastic Leukemia

Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia

Regulation of SIRT2 Levels for Human Non-Small Cell Lung Cancer Therapy.